Vol 5, No 3 (2020)
Letter to the Editor
Published online: 2020-06-15

open access

Page views 669
Article views/downloads 1242
Get Citation

Connect on Social Media

Connect on Social Media

Interferon lambda with remdesivir as a potential treatment option in COVID-19

Ishag Adam1, Lukasz Szarpak2, Krzysztof Jerzy Filipiak3, Jacek Smereka4, Marek Dabrowski5, Saeid Ghavami67, Milosz Jaguszewski8
Disaster Emerg Med J 2020;5(3):174.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020 [Epub ahead of print].
  2. Malik YS, Sircar S, Bhat S, et al. Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments. Vet Q. 2020; 40(1): 68–76.
  3. Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020; 295(20): 6785–6797.
  4. Hemann EA, Schwerk J, Savan R. IFN-λ 'guts' neutrophil-mediated inflammation. Nat Immunol. 2017; 18(10): 1061–1062.
  5. Mordstein M, Neugebauer E, Ditt V, et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol. 2010; 84(11): 5670–5677.